Clinical trials: Advanced Chronic Liver Disease
Hepatitis C
Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)
This is a non-randomized, open-label study of a fixed dose combination (FDC) of elbasvir (50 mg) and grazoprevir (100 mg) (EBR/GZR or MK-5172A) in participants with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection with…
- Trial name
- NCT03143998
- Testing
- MK-5172A
- Sponsor
- Merck Sharp & Dohme LLC
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Biliary Tract Neoplasms, Cholangiocarcinoma
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Background: Biliary tract cancers are rare but they are serious. Researchers want to see if a certain drug helps the immune system fight cancer cells. The drug is called pembrolizumab.
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer
- Trial name
- NCT03111732
- Testing
- Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Cohort Study
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN-C (NCT05740358)
- Where
- 14 sites in United States
- Volunteers
- 1,222 people
- Sponsor
- Northwestern University
Chronic Hepatitis C
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
A study on regression of liver fibrosis assessed by transient elastography after Daclatasvir and Asunaprevir combined treatment in advanced fibrotic/cirrhotic patients with chronic hepatitis C genotype 1b Infection
- Trial name
- RELIF-C (NCT02865369)
- Testing
- Daclatasvir and Asunaprevir
- Where
- 10 sites in South Korea
- Volunteers
- 103 people
- Sponsor
- Sang Gyune Kim
HCC in Chronic HCV Patients With Advanced Liver Fibrosis
Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals
Chronic HCV infection has relatively slow rate of progression. Liver fibrosis is the main sequlae and usually progressed to cirrhosis after long period (10 to 20 years) [6].
- Trial name
- NCT03884062
- Testing
- DAAs
- Volunteers
- 3,000 people
- Sponsor
- Egyptian Liver Hospital
Chronic Liver Disease and Cirrhosis, Chronic Liver Disease
hepatomiR cACLD Study
This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic…
- Conditions
- Chronic Liver Disease and Cirrhosis, Chronic Liver Disease, Portal Hypertension
- Trial name
- NCT06432582
- Testing
- hepatomiR
- Where
- Austria
- Volunteers
- 156 people
- Sponsor
- Karl Landsteiner University of Health Sciences
Lymphoma, Small Intestine Cancer
S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049400
- Testing
- BMS-247550
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- SWOG Cancer Research Network
Portal Hypertension, Chronic Advanced Liver Disease
Velacur by Sonic Incytes for Portal Hypertension
This is a cross sectional study that evaluates the relationship between LSM (liver stiffness measurement) by Liver Incytes in patients with cACLD (compensated advanced chronic liver disease) and manifestations of portal…
- Trial name
- NCT04576897
- Testing
- Velacur
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Indiana University
Advanced Chronic Liver Disease, NASH
Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using VCTE by FibroScan.
Hypothesis: The severity of portal hypertension in compensated advanced chronic liver disease (cACLD) can be assessed using vibration controlled transient elastography (VCTE) via the FibroScan® 502 Touch by measuring SS (splenic…
- Trial name
- NCT03778411
- Testing
- VCTE with splenic stiffness measurement
- Where
- United States
- Volunteers
- 298 people
- Sponsor
- Indiana University
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Cirrhosis, Advanced Chronic Liver Disease
Natural History of Advanced Chronic Liver Diseases
This is a retrospective-prospective registry cohort study. Patients with advanced chronic liver disease (ACLD) will be prospectively invited to this study. The study follow-up duration will be 10 years.
- Trial name
- NCT07042308
- Testing
- Transient elastography
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Hepatitis C
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced…
- Trial name
- NCT02319031
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 10 sites in Australia, France
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis
The rate of sustained virological response to a course of standard antiviral therapy (peg-interferon plus ribavirin) of patients with chronic hepatitis C infected by genotype 1 with advanced fibrosis (>F2) is rather low.
- Trial name
- RIBACIR (NCT00840489)
- Testing
- Ribavirin, Colchicine
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Universitario Ramon y Cajal
Liver Disease Chronic, Cirrhosis
cACLD in Patients With Alcohol Use Disorder in the Hospital Detoxification Unit
The aim of this study is to conduct a quick assessment of potential liver damage caused by chronic alcohol consumption. Taking advantage of the patient's admission to a specialized detoxification unit, several tests will be…
- Conditions
- Liver Disease Chronic, Cirrhosis, Detoxification, Alcohol Abuse/Dependence
- Trial name
- HEP-UHD (NCT06838468)
- Testing
- Screening of compensated advance chronic liver disease
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Corporacion Parc Tauli
Locally Advanced Cancer, Metastatic Cancer
Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool
Every day many patients affected by chronic life-limiting illnesses are admitted into Internal Medicine wards, coming from the Emergency Department.
- Conditions
- Locally Advanced Cancer, Metastatic Cancer, Chronic Respiratory Failure, Chronic Heart Failure
- Trial name
- SST2017 (NCT04143230)
- Testing
- Screening for PC by means of two different screening tools
- Where
- Italy
- Volunteers
- 660 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
This phase II trial is studying the effectiveness of combining thalidomide and chemoembolization in treating patients who have liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT00006016
- Testing
- thalidomide, doxorubicin hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Hepatitis C Virus Chronic Infection
Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma
CP-675,206 (tremelimumab) is a fully humanized monoclonal antibody that binds to activated T lymphocytes and by enhancing their activation may produce a stimulation of the immune response against tumoral or viral antigens.
- Trial name
- NCT01008358
- Testing
- CP 675,206
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers